Condition
Esophageal Squamous Cell Carcinoma by AJCC V8 Stage
Total Trials
4
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
P 2 (4)
Trial Status
Unknown2
Active Not Recruiting1
Not Yet Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT06010303Phase 2Active Not Recruiting
A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
NCT05791136Phase 2Not Yet RecruitingPrimary
Immunotherapy After Radiotherapy in Elderly ESCC
NCT05449483Phase 2UnknownPrimary
Conversion of Tislelizumab Combined With Chemotherapy in Unresectable Esophageal Squamous Cell Carcinoma
NCT04006041Phase 2UnknownPrimary
Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer
Showing all 4 trials